Patents by Inventor Isabel Delgado
Isabel Delgado has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12246006Abstract: It relates to a single-dose packaging unit which is a blow-fill-seal (BFS) container which comprises a sterile pharmaceutical or veterinary liquid composition which is a solution, wherein a) the composition comprises a therapeutically effective amount of clotrimazole or a pharmaceutically or veterinary acceptable salt thereof, together with one or more pharmaceutically or veterinary acceptable excipients or carriers, and b) the container has a volume from 0.05 to 8 mL, with the condition that the water content of the composition is equal to or lower than 4% by weight with respect to the total composition weight. It also relates to a secondary packaging comprising one or more single-dose packaging units.Type: GrantFiled: February 18, 2020Date of Patent: March 11, 2025Assignee: LABORATORIOS SALVAT, S.A.Inventors: Maria Mar Terraz Mendoza, Javier Sanagustín Aquilué, Adolfo Téllez Molina, María Isabel Delgado Gañán
-
Patent number: 11672798Abstract: The present invention provides a combination comprising ciprofloxacin, or a pharmaceutically acceptable salt thereof, and fluocinolone acetonide for use in the prevention and/or treatment of an ocular disease, wherein the prevention and/or treatment comprises the topical administration of the combination. The invention also provides an ophthalmic topical pharmaceutical composition comprising the combination together with at least one ophthalmically acceptable excipient, diluent, or carrier, for use in the prevention and/or treatment of an ocular disease, wherein the prevention and/or treatment comprises the topical administration of the composition.Type: GrantFiled: December 23, 2021Date of Patent: June 13, 2023Assignee: LABORATORIOS SALVAT, S.A.Inventors: Sandra Marchán Sancho, Francisca Toribio Santisteban, María Isabel Delgado Gañán
-
Publication number: 20220387422Abstract: The present invention provides a combination comprising ciprofloxacin, or a pharmaceutically acceptable salt thereof, and fluocinolone acetonide for use in the prevention and/or treatment of an ocular disease, wherein the prevention and/or treatment comprises the topical administration of the combination. The invention also provides an ophthalmic topical pharmaceutical composition comprising the combination together with at least one ophthalmically acceptable excipient, diluent, or carrier, for use in the prevention and/or treatment of an ocular disease, wherein the prevention and/or treatment comprises the topical administration of the composition.Type: ApplicationFiled: December 23, 2021Publication date: December 8, 2022Inventors: Sandra MARCHÁN SANCHO, Francisca Toribio Santisteban, MarÍa Isabel DELGADO GAÑÁN
-
Publication number: 20220133695Abstract: It relates to a single-dose packaging unit which is a blow-fill-seal (BFS) container which comprises a sterile pharmaceutical or veterinary liquid composition which is a solution, wherein a) the composition comprises a therapeutically effective amount of clotrimazole or a pharmaceutically or veterinary acceptable salt thereof, together with one or more pharmaceutically or veterinary acceptable excipients or carriers, and b) the container has a volume from 0.05 to 8 mL, with the condition that the water content of the composition is equal to or lower than 4% by weight with respect to the total composition weight. It also relates to a secondary packaging comprising one or more single-dose packaging units.Type: ApplicationFiled: February 18, 2020Publication date: May 5, 2022Inventors: Maria Mar TERRAZ MENDOZA, Javier SANAGUSTÍN AQUILUÉ, Adolfo TÉLLEZ MOLINA, María Isabel DELGADO GAÑÁN
-
Publication number: 20200390729Abstract: The invention relates to a new therapeutic approach for treatment and/or prevention of a disease of the posterior segment of the eye, in particular for retinal and optic nerve pathologies. Dobesilic acid and/or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, are proposed for use topically administered onto eye surface. There are also disclosed new compositions comprising dobesilic acid and/or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, adapted for performing the treatment and/or prevention of diseases of the posterior segment of the eye.Type: ApplicationFiled: November 29, 2018Publication date: December 17, 2020Inventors: Xavier CAPDEVILA NORTES, Javier SANAGUSTIN AQUILUE, Maria Isabel DELGADO GANAN
-
Patent number: 10857160Abstract: It relates to an oil-in-water nanoemulsion composition having a continuous aqueous phase and dispersed oil droplets, wherein the nanoemulsion comprises: (a) clobetasol; (b) one or more oil components; and (c) one or more surfactants; together with one or more pharmaceutically acceptable excipients or carriers wherein: the osmolality of the nanoemulsion is comprised from 100 mOsm/Kg to 500 mOsm/Kg; the droplet average size measured by Dynamic light scattering is comprised from 1 nm to 500 nm; the weight ratio between the oil components and the sum of the oil components and one or more surfactants is comprised from 0.001 to 0.5; the weight ratio between the oil component and clobetasol is comprised from 1:1 to 200:1; and the weight ratio between the surfactant and clobetasol is comprised from 2:1 to 200:1. It also relates to processes for its preparation, its use as a medicament, and in the prophylaxis and/or treatment of inflammatory diseases or conditions.Type: GrantFiled: January 18, 2018Date of Patent: December 8, 2020Assignee: LABORATORIOS SALVAT, S.A.Inventors: Javier Sanagustin Aquilue, María Del Carmen Lendínez Gris, Maria Isabel Delgado Gañán
-
Patent number: 10660848Abstract: The present invention relates to a sterile ophthalmic composition comprising castor oil and a medium chain triglyceride, to its use in medicine, in particular for the treatment and/or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, floppy eyelid syndrome, thyroid ophthalmopathy, pterygium, conjunctivochalasis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, corneal ulcers induced by physical or chemical agents, keratitis, episcleritis and uveitis.Type: GrantFiled: July 7, 2017Date of Patent: May 26, 2020Assignee: LABORATORIOS SALVAT, S.A.Inventors: Francisca Izquierdo Torres, Sandra Marchan Sancho, Isabel Delgado Gañán
-
Publication number: 20190298737Abstract: It relates to an oil-in-water nanoemulsion composition having a continuous aqueous phase and dispersed oil droplets, wherein the nanoemulsion comprises: (a) clobetasol; (b) one or more oil components; and (c) one or more surfactants; together with one or more pharmaceutically acceptable excipients or carriers wherein: the osmolality of the nanoemulsion is comprised from 100 mOsm/Kg to 500 mOsm/Kg; the droplet average size measured by Dynamic light scattering is comprised from 1 nm to 500 nm; the weight ratio between the oil components and the sum of the oil components and one or more surfactants is comprised from 0.001 to 0.5; the weight ratio between the oil component and clobetasol is comprised from 1:1 to 200:1; and the weight ratio between the surfactant and clobetasol is comprised from 2:1 to 200:1. It also relates to processes for its preparation, its use as a medicament, and in the prophylaxis and/or treatment of inflammatory diseases or conditions.Type: ApplicationFiled: January 18, 2018Publication date: October 3, 2019Applicant: Laboratorios Salvat, S.A.Inventors: Javier SANAGUSTIN AQUILUE, María Del Carmen LENDÍNEZ GRIS, Maria Isabel DELGADO GAÑÁN
-
Publication number: 20180008538Abstract: The present invention relates to a sterile ophthalmic composition comprising castor oil and a medium chain triglyceride, to its use in medicine, in particular for the treatment and/or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, floppy eyelid syndrome, thyroid ophthalmopathy, pterygium, conjunctivochalasis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, corneal ulcers induced by physical or chemical agents, keratitis, episcleritis and uveitis.Type: ApplicationFiled: July 7, 2017Publication date: January 11, 2018Inventors: Francisca Izquierdo Torres, Sandra Marchan Sancho, Isabel Delgado Gañán
-
Publication number: 20160331563Abstract: A prosthetic device adapted to be worn on a lower limb of a patient is provided. The prosthetic device includes a socket having an inner surface of which contacts the limb of the patient when the prosthetic device is worn by the patient. Pressure sensors are provided on the inner surface of the socket which measure pressure at the socket-limb interface when the prosthetic device is worn by the patient. The prosthetic device also includes a processor and a wireless transceiver. The processor receives data from the pressure sensors and wirelessly transmits the data to a remote wireless device. A system including the prosthetic device and a remote wireless device is also provided. The remote wireless device can display a map of pressure as a function of sensor location at the socket-limb interface and issue a warning to the patient if the pressure at a sensor location exceeds a specified value. Methods of using the prosthetic to monitor pressure at the socket-limb interface are also provided.Type: ApplicationFiled: May 16, 2016Publication date: November 17, 2016Inventors: Justin M. KANE, Mariah Anne CODY, Kayla Marie DELANEY, Laura Isabel Delgado GARCIA, Istvan MORITZ, Darren Kailung JENG
-
Publication number: 20130237579Abstract: The present invention relates to stable pharmaceutical compositions comprising one or more HMG-CoA reductase inhibitors, processes for preparing the stable compositions and uses for the compositions. The stable pharmaceutical compositions of the invention may be used, in particular, for the treatment of hyperlipoproteinemia and atherosclerosis.Type: ApplicationFiled: July 11, 2008Publication date: September 12, 2013Inventors: Timothy Stanley, Isabel Delgado, Estela Llorens, Eva Munoz
-
Publication number: 20130136795Abstract: The present invention relates to stable solid pharmaceutical compositions comprising valsartan as the active pharmaceutical ingredient. Optionally the compositions comprise one or more further active pharmaceutical ingredients. The invention further relates to methods for preparing said compositions and to the use of said compositions in the treatment or prevention of angiotensin receptor mediated disorders, in particular hypertension and related disorders.Type: ApplicationFiled: August 8, 2008Publication date: May 30, 2013Applicants: Poligono Merck, Generics [UK] LimitedInventors: Miguel Barrero, Isabel Delgado